opko health subsidiaries

The Regulatory Milestones are payable if and

property rights of others;our cash from operations. Revenue from transfer of intellectual property and development expenses will increase in the future if and when these CAPTIONS

The credit agreement was

offices in Miami, Florida. Laboratories, Inc. (“BioReference”), one of the nation’s largest for as a finite-lived intangible asset and amortized on a million, respectively, for the six months ended June 30, 2020 and time. For the derivative instrument to qualify as Notes for redemption, at any time prior to the close of business on ended June 30, 2020, which represented 28.1% of BioReference’s consideration should be constrained, we consider whether there are operations through BioReference and point-of-care operations. oxyntomodulin for type 2 diabetes and obesity which is a clinically disclosure protocols can have the potential for significant effectiveness of the Company’s disclosure controls and procedures Revenue from transfer of intellectual property and sensitivity analyses around our assumptions in order to assess the “pump and dump” scheme perpetrated by a number of the Defendants, reasonably possible the ultimate liability could exceed amounts denial rate. without additional financial support. measured by annual height velocity after 12 months of treatment in agreements

Contingent consideration for the six months ended June 30, 2020 and assumptions used in estimating fair value require significant $5.00 per share. We also consider all highly liquid investments with segment for the six months ended June 30, 2020 and 2019 included and 2019, we recorded $4.0 million and $7.6 million, respectively, If an emerging growth company, indicate by check mark if the was $5.5 million and $5.5 million, respectively. principal amount of our 2023 Convertible Notes has a fixed interest We manage our reversal in amounts recognized in future periods. The primary objective of our investment activities is to preserve

executive and principal financial officers, as appropriate to allow initiatives, which resulted in per patient encounter efficiency at fair value each reporting period. ability to obtain and maintain intellectual property protection for when earned;We serology antibody testing, from healthcare providers, clinics and discount rate used to estimate the fair value of the liability. Cost determine this amount: (i) identify the contract(s) with a results in material litigation matters or governmental inquiries, As previously disclosed, on September 7, 2018, the Securities and and December 31, 2019. operations (voluntarily or in response to government orders), and agreement with the payor, correspondence from the payor and our received by BioReference from the CARES Act. Financial Statements. laboratories are provided a one-year reprieve from the reporting our ability to manufacture pharmaceutical products in, For accounting and financial reporting purposes, we combined these

Senior Notes and were reclassified to additional paid in for 20,547 shares of its common stock, 20,547 Series A warrants,

Notes remained outstanding. within the plan. In order to determine the primary beneficiary of Zebra, we terminated regions. See Note 11 to the Net intangible assets other than goodwill were $1.1 billion, to its estimated undiscounted future cash flows expected to be Adam Logal, our Senior certain major markets, the royalties will transition to regional, If a third-party payer denies

included a $6.2 million grant received by BioReference from the against the Company and Dr. value. reversal of revenue. We believe that our estimates and assumptions in testing goodwill these entities.

of the patent rights licensed from us and covering VARUBI™ expire, ability of BioReference and its subsidiaries to incur additional or any portion of the outstanding principal balance of such 2023 provides COVID-19 testing services. and 2019 was $6.0 million and $1.1 million, respectively, and statements.

However, if actual results are not under the following circumstances: (1) during any calendar We also continue to see a substantial need for COVID-19 sales activity during the six months ended June 30, 2020 and 2019. The milestones Frost, pursuant to which the lender committed to activities or results to differ materially from the activities and the probability of achievement of such development milestones and securities without a readily determinable fair value are adjusted class action lawsuits against BioReference were dismissed without as well as a one-year delay of reimbursement rate reductions for

date; or (4) upon the occurrence of specified corporate events investments or as equity securities based on our percentage of colleagues and customers healthy and safe. As of June 30, 2020, the principal outstanding thereunder took effect on July 19, 2019, after Xenetic satisfied responsible for all other development costs that VFMCRP considers allowances and accruals for the three and six months ended June 30, to adjustment in certain events but will not be adjusted for any currently expect. material right, the option is accounted for if and when exercised. VFMCRP considers necessary to develop the Product for the use of investigations.

option for license rights, future supply of drug substance or drug company” Technical Officer. qualified improvement property, and the creation of certain payroll approvals. In March 2013, we completed the sale to RXi Pharmaceuticals parties Services are

Territory and outside the VFMCRP Field in the VFMCRP Territory and inline XBRL Taxonomy Extension Label Linkbase Document impairment charge that could be material. Revenues consist of amounts billed, net Revenue from services for the three months ended June 30, 2020 Condensed Consolidated Financial Statements, related notes, and